BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

sanofi pasteur, Acambis Campus 

38 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-761-4200 Fax: 617-464-1742


SEARCH JOBS

Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognized internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. In January 2006, Acambis submitted the first portion of a Biologics License Application with the FDA to seek licensure for the vaccine and expects a decision by the FDA by the end of the year. Acambis is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health.

Acambis’ Miami-based subsidiary Berna Products Corporation markets Vivotif®, the world's only licensed oral typhoid vaccine, in North America. The company’s investigational vaccine against Japanese encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. Acambis also has the most advanced investigational vaccine against the West Nile virus, which has spread to 48 states in the last six years, and a vaccine against Clostridium difficile bacteria, a leading cause of hospital-acquired infections.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, with operations in Canton, Massachusetts; Rockville, Maryland; and Miami, Florida. We invite you to learn more about Acambis and our employment opportunities at www.acambis.com.

Last Updated: 02-15-2006

 Key Statistics


Email: acambis@acambis.com
Ownership: Public

Web Site: sanofi pasteur, Acambis Campus
Employees:
Symbol: ACAM
 



Industry
Biotechnology






 Company News
Vivalis Grants Research License to Acambis (ACAM) to Evaluate E B66(R) Cell Line for Viral Vaccines Production 7/9/2008 8:38:59 AM    More...
Crucell N.V. (CRXL) Announces PER.C6(R) Licensing Agreement with Acambis (ACAM) 11/20/2007 4:05:33 PM    More...
Acambis (ACAM) Joins Forces With Sanofi Pasteur (SASY.PA) to Develop West Nile Virus Vaccine 11/13/2007 7:08:08 AM    More...
Acambis (ACAM) Says Japanese Encephalitis Trial Positive 10/30/2006 3:17:35 PM    More...
Acambis PLC (ACAM) Release: Research Update 9/12/2006 11:06:16 AM    More...
Acambis PLC (ACAM) - Acambis (ACAM) Wins MVA Case 9/7/2006 4:00:34 PM    More...
Peter Fellner To Become New Chairman Of Acambis (ACAM) 7/12/2006 4:50:32 PM    More...
BioSpace, Inc. And Massachusetts Biotechnology Council, Inc. Unveil 2006 Genetown™ Campaign 12/14/2005 6:22:26 PM    More...
Cangene Corporation (CC:CNJ) Wins UK Government Contract With Acambis PLC (ACAM) For $14.4 Million 10/19/2005 5:12:12 PM    More...

//-->